UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

• PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  UEI UNVDZNFA8R29

  $2.2M

  Subcontractor to this prime · 1 sub-award · latest Aug 22, 2024

  • National Institutes of Health
  • “MAIN CONTRACT AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF JOANNE FLYNN WILL PERFORM WORK UNDER PROJECT 1, “PROTECTION FROM INFECTION AFTER IV BCG VACCINATION,” AND PROJECT 2, “NATURAL CONTROL OF MTB INFECTION IN NHPS”; AND ALSO WORK WITH THE LABORATORY OF JOSHUA MATTILA TO EVALUATE RNASCOPE LABELLING OF INFECTED TISSUES. SPECIFICALLY, DR. FLYNN WILL: • AS CO-PI, PROVIDE SCIENTIFIC LEADERSHIP FOR THE OVERALL CONTRACT WITH DRS. FORTUNE AND BOOM. • AS LEADER FOR PROJECT 1, DESIGN, IMPLEMENT, AND OVERSEE THE NONHUMAN PRIMATE (NHP) VACCINE STUDIES, OF SIV CO-INFECTION ON IV-BCG ELICITED IMMUNITY. WORK WILL ALSO ASSESS THE PROTECTIVE SIGNALS ASSOCIATED WITH A SUBUNIT VACCINE, TB-MAPS, IN COMBINATION WITH INTRADERMAL BCG VACCINATION. • AS LEADER FOR PROJECT 2, DESIGN, IMPLEMENT, AND OVERSEE THE NONHUMAN PRIMATE (NHP) STUDIES OF CONCOMITANT IMMUNITY (INCLUDING HETEROLOGOUS CHALLENGE), PROTECTION BY CD4 CELLS, AND PROTECTION BY CD8 CELLS. • PROVIDE SAMPLES FROM THE NHP STUDIES TO THE TECHNOLOGY AND MECHANISTIC CORES FOR ANALYSIS. A DETAILED LIST OF SAMPLES IS INCLUDED BELOW. • WORK WITH THE LABORATORY OF JOSHUA MATTILA TO GENERATE FIXED INFECTED CELL LINES AND NHP TISSUE THAT WILL BE USED TO EVALUATE RNASCOPE LABELLING OF MTB IN SITU. • MEET THE DELIVERABLES SET FORTH IN THE IMPACTB STATEMENT OF WORK, AS LISTED BELOW. SAMPLES. WE ANTICIPATE THAT SAMPLES WILL BE PROVIDED TO THE FOLLOWING IMPACTB COLLABORATORS, SUBJECT TO CHANGE AS THE SCIENTIFIC PROGRAM DICTATES: 1. SAMUEL BEHAR, UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL: BAL, BLOOD, BONE MARROW FOR TCR IDENTIFICATION 2. ALEX SHALEK, RAGON INSTITUTE: GRANULOMA ARRAYS FOR SCRNASEQ 3. RYAN MCNAMARA, RAGON INSTITUTE: BAL, GRANULOMAS, LUNG HOMOGENATE SUPERNATANTS FOR SYSTEMS SEROLOGY 4. SARAH FORTUNE, HARVARD T.H. CHAN SCHOOL: BAL, GRANULOMAS, LUNG, LYMPH NODES FOR BARCODES AND CEQ; ALSO BAL, BLOOD FOR INNATE MECHANISM ASSAYS 5. BRYAN BRYSON, M”
• LEIDOS BIOMEDICAL RESEARCH INC

  UEI HV8BH9BPG8Y9

  $1.6M

  Subcontractor to this prime · 1 sub-award · latest Jul 1, 2025

  • National Institutes of Health
  • “PCL-02 M3 SUBCONTRACTS”
• TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE

  UEI GM1XX56LEP58

  $789.1K

  Subcontractor to this prime · 3 sub-awards · latest Apr 16, 2026

  • National Institutes of Health
  • “IN THIS CEIRR APPLICATION, THE LAKDAWALA LAB AT THE UNIVERSITY OF PITTSBURGH WILL LEVERAGE OUR INFLUENZA TRANSMISSION AND PATHOGENESIS EXPERTISE TO ASSIST IN MULTIPLE PROJECTS. IN ADDITION, WE USE OUR EXTENSIVE KNOWLEDGE OF VIRAL PROPERTIES THAT PROMOTE AIRBORNE TRANSMISSION OF INFLUENZA VIRUSES TO CHARACTERIZE EMERGING ZOONOTIC STRAINS EACH YEAR. OUR SPECIFIC STATEMENT OF WORK FOR EACH ELEMENT OF THE CEIRR APPLICATION IS DETAILED BELOW. REQUIRED #3: INFLUENZA SURVEILLANCE, RISK ASSESSMENT AND RESPONSE TASKS: 1. ASSESS THE REPLICATION OF EMERGING SWINE AND AVIAN VIRUSES IN PRIMARY HUMAN BRONCHIAL EPITHELIAL CELLS. 2. ASSIST IN MOLECULAR CHARACTERIZATION OF EMERGING SWINE AND AVIAN VIRUSES. REQUIRED #4: PRE-PANDEMIC AND PANDEMIC RESPONSE TASKS: 1. PERFORM FERRET PATHOGENESIS STUDIES FOR 1-3 INFLUENZA VIRUSES PER YEAR. (UP TO 12 ANIMALS PER YEAR) 2. PERFORM FERRET AIRBORNE TRANSMISSION STUDIES IN NAÏVE ANIMALS FOR 1-3 VIRUSES PER YEAR. (24 ANIMALS PER YEAR) 3. ASSESS TRANSMISSIBILITY OF EMERGING VIRUSES IN FERRETS WITH PRE-EXISTING IMMUNITY. (16 ANIMALS PER YEAR) 4. PERFORM MOLECULAR CHARACTERIZATION OF THESE VIRUSES TO ASSESS GROWTH IN PRIMARY HUMAN AIRWAY CELLS, STABILITY IN SIMULATED EXPELLED DROPLETS, RECEPTOR AND CELL TROPISM, AND NA ACTIVITY. REQUIRED #5: PATHOGENESIS AND IMMUNE RESPONSE RESEARCH (PROJECT 2: IMMUNITY CHANGING OVER TIME). TASKS: 1. PERFORM FERRET STUDIES TO ASSESS IMMUNE RESPONSES TO VACCINATION IN THE CONTEXT OF PRE-EXISTING IMMUNITY. (8 ANIMALS PER YEAR) 2. PERFORM FERRET STUDIES TO DEFINE THE LONGEVITY OF ANTIBODY RESPONSES IN THE FERRET MODEL (4 ANIMALS PER YEAR)”
  • “LE SAGE SCOPE OF WORK FOR PENN-CEIRR OPTION 18.L THIS CEIRR CONCEPT PROPOSAL HAS TWO DISTINCT AIMS THAT WILL ENABLE CHARACTERIZATION OF H5N1 HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI) VIRUS IN TERMS OF HOST AND ENVIRONMENTAL FACTORS THAT AFFECT TRANSMISSIBILITY. H5N1 HPAI STRAINS THAT ARE IMPORTANT TO THE DAIRY CATTLE OUTBREAK WILL BE ASSESS IN THE FOLLOWING AIMS. THERE ARE MANY IN VITRO CHARACTERISTICS THAT HAVE AN IMPACT ON EFFICIENT TRANSMISSION OF INFLUENZA VIRUS. IN AIM 1, I WILL CHARACTERIZE H5N1 HPAI STRAINS TO BETTER UNDERSTAND HOST TROPISM AND ENVIRONMENTAL STABILITY. THE FOLLOWING TASKS WILL BE ACCOMPLISHED: 1. EXAMINE REPLICATION KINETICS OF H5N1 HPAI IN PRIMARY HUMAN AIRWAY EPITHELIAL CELLS AND COMPARE IT TO A SEASONAL INFLUENZA VIRUS. 2. PERFORM SINGLE CELL RNA SEQUENCING ON THE INFECTED PRIMARY HUMAN AIRWAY EPITHELIAL CELLS TO COMPARE HOST TROPISM BETWEEN H5N1 HPAI AND SEASONAL INFLUENZA VIRUS. 3. COMPARE THE SECRETED CYTOKINES AND CHEMOKINES FROM H5N1 HPAI OR SEASONAL INFLUENZA VIRUS INFECTED PRIMARY HUMAN AIRWAY EPITHELIAL CELLS USING LUMINEX ASSAY. 4. DETERMINE THE ENVIRONMENTAL STABILITY UNDER A RANGE OF RELATIVE HUMIDITIES IN STATIONARY DROPLETS THAT CONTAIN MUCUS, COLLECTED FROM PRIMARY HUMAN AIRWAY EPITHELIAL CELLS. PRE-EXISTING IMMUNITY IS AN IMPORTANT BARRIER TO INFLUENZA VIRUS TRANSMISSION. IN AIM 2, I WILL ASSESS THE IMPACT OF SEASONAL VACCINATION IN FERRETS PRIOR TO CHALLENGE WITH H5N1 HPAI. THE FOLLOWING TASKS WILL BE ACCOMPLISHED: 1. PERFORM FERRET PATHOGENESIS AND SURVIVAL STUDIES IN FERRETS THAT HAVE BEEN VACCINATED WITH A SEASONAL INFLUENZA VIRUS THREE MONTHS PRIOR TO INTRANASAL CHALLENGE. 2. AS AIRBORNE TRANSMISSION IS NOT EFFICIENT FOR HPAI STRAINS, I WILL LEVERAGE THE AEROBIOLOGY CORE AT THE UNIVERSITY OF PITTSBURGH TO COMPARE THE SUSCEPTIBILITY OF VACCINATED FERRETS TO AEROSOL CHALLENGE OF H5N1 HPAI CHALLENGE. 3. PERFORM SEROLOGICAL ASSAYS TO DETERMINE THE LEVELS OF CROSS-REACTIVE HA AND NA ANTIBODIES GENERATED BY THESE VACCINATED FE”
  • “LAKDAWALA STATEMENT OF WORK IN THIS CEIRR APPLICATION, THE LAKDAWALA LAB AT THE UNIVERSITY OF PITTSBURGH WILL LEVERAGE OUR INFLUENZA TRANSMISSION AND PATHOGENESIS EXPERTISE TO ASSIST IN MULTIPLE PROJECTS. IN ADDITION, WE USE OUR EXTENSIVE KNOWLEDGE OF VIRAL PROPERTIES THAT PROMOTE AIRBORNE TRANSMISSION OF INFLUENZA VIRUSES TO CHARACTERIZE EMERGING ZOONOTIC STRAINS EACH YEAR. OUR SPECIFIC STATEMENT OF WORK FOR EACH ELEMENT OF THE CEIRR APPLICATION IS DETAILED BELOW. REQUIRED #3: INFLUENZA SURVEILLANCE, RISK ASSESSMENT AND RESPONSE TASKS: 1. ASSESS THE REPLICATION OF EMERGING SWINE AND AVIAN VIRUSES IN PRIMARY HUMAN BRONCHIAL EPITHELIAL CELLS. 2. ASSIST IN MOLECULAR CHARACTERIZATION OF EMERGING SWINE AND AVIAN VIRUSES. REQUIRED #4: PRE-PANDEMIC AND PANDEMIC RESPONSE TASKS: 1. PERFORM FERRET PATHOGENESIS STUDIES FOR 1-3 INFLUENZA VIRUSES PER YEAR. (UP TO 12 ANIMALS PER YEAR) 2. PERFORM FERRET AIRBORNE TRANSMISSION STUDIES IN NAÏVE ANIMALS FOR 1-3 VIRUSES PER YEAR. (24 ANIMALS PER YEAR) 3. ASSESS TRANSMISSIBILITY OF EMERGING VIRUSES IN FERRETS WITH PRE-EXISTING IMMUNITY. (16 ANIMALS PER YEAR) 4. PERFORM MOLECULAR CHARACTERIZATION OF THESE VIRUSES TO ASSESS GROWTH IN PRIMARY HUMAN AIRWAY CELLS, STABILITY IN SIMULATED EXPELLED DROPLETS, RECEPTOR AND CELL TROPISM, AND NA ACTIVITY. REQUIRED #5: PATHOGENESIS AND IMMUNE RESPONSE RESEARCH (PROJECT 2: IMMUNITY CHANGING OVER TIME). TASKS: 1. PERFORM FERRET STUDIES TO ASSESS IMMUNE RESPONSES TO VACCINATION IN THE CONTEXT OF PRE-EXISTING IMMUNITY. (8 ANIMALS PER YEAR) 2. PERFORM FERRET STUDIES TO DEFINE THE LONGEVITY OF ANTIBODY RESPONSES IN THE FERRET MODEL (4 ANIMALS PER YEAR)”
• HII MISSION TECHNOLOGIES CORP

  UEI G5H7HWC4L2R5

  $733.2K

  Subcontractor to this prime · 1 sub-award · latest Mar 12, 2024

  • Federal Acquisition Service
  • “SUBCONTRACTOR WILL FACILITATE THE COLLABORATION OF MISSION PARTNERS AND THEIR COMPONENTS TO ASSESS TECHNOLOGY CAPABILITY EFFECTIVENESS TO DETECT, DETER AND DEFEAT SECURITY THREATS THAT MAY ADVERSELY IMPACT US FORCE AND PARTNERS”
• THE MEDICAL COLLEGE OF WISCONSIN, INC.

  UEI E8VWJXMMUQ67

  $484.1K

  Subcontractor to this prime · 1 sub-award · latest Aug 26, 2024

  • Defense Health Agency
  • “POINT-MTBI: PROSPECTIVE STUDY OF POINT-OF-CARE BLOOD-BASED BIOMARKERS IN ACUTE MILITARY, CIVILIAN, AND SPORT-RELATED MILD TRAUMATIC BRAIN INJURY (MTBI)”
• LEIDOS, INC.

  UEI MYKLJHTX3MM7

  $210K

  Subcontractor to this prime · 3 sub-awards · latest Sep 2, 2026

  • Department of Energy
  • “PROCURED GOODS AND/OR SERVICES IN SUPPORT OF CONTRACT SOW.”
  • “PROCURED GOODS AND/OR SERVICES BETWEEN 31-JUL-26 AND 30-DEC-28 IN SUPPORT OF CONTRACT SOW.”
• NEUROWAVE SYSTEMS INC

  UEI J8LLPBAEMJG3

  $200K

  Subcontractor to this prime · 1 sub-award · latest Feb 18, 2026

  • Department of the Navy
  • “COLLABORATIVE RESEARCH STUDY.”
• LEIDOS, INC.

  UEI QLNMVC12KWY3

  $99.9K

  Subcontractor to this prime · 1 sub-award · latest Jun 1, 2026

  • Federal Highway Administration
  • “PROCURED GOODS AND/OR SERVICES BETWEEN 01-JUN-26 AND 12-SEP-26 IN SUPPORT OF CONTRACT SOW.”
• LUNA LABS USA LLC

  UEI M6JVSYRQRYM9

  $90K

  Subcontractor to this prime · 1 sub-award · latest Dec 22, 2025

  • Department of the Navy
  • “CONDUCT EXPERIMENTS AND CHARACTERIZATION.”
• FLUOR MARINE PROPULSION, LLC

  UEI CWHMVCX7K1N6

  $68.1K

  Subcontractor to this prime · 1 sub-award · latest May 1, 2026

  • Department of Energy
  • “RELEASE 14 UNDER UNIVERSITY OF PITTSBURGH MA 140449”
• OREGON STATE UNIVERSITY

  UEI MZ4DYXE1SL98 · not in the directory yet

  $41.6K

  Subcontractor to this prime · 1 sub-award · latest Feb 16, 2026

  • Department of the Army
  • “ER24-C5-4250 BIOMIMETIC CHROMATOGRAPHY FOR RAPID ASSESSMENT OF BIOACCUMULATION (BIOCRAB) IN PFAS-IMPACTED AQUATIC FOOD WEBS”

• MED-ALLY, LLC

  UEI RKR5QQ6D9AH9 · not in the directory yet

  $4.1M

  Subcontracted by this company · 1 sub-award · latest Apr 28, 2025

  • Department of the Navy
  • “RESEARCH IAW SOW (BASE)AWARD TO UPITT (BG PLUS)”
• THERMAQUIL, INC.

  UEI S8FTDLJNX2K5 · not in the directory yet

  $3.3M

  Subcontracted by this company · 1 sub-award · latest Apr 24, 2025

  • Department of the Navy
  • “RESEARCH IAW SOW (BASE)AWARD TO UPITT (BG PLUS)”
• METROHEALTH SYSTEM, THE

  UEI FM8VV9SAL6M3 · not in the directory yet

  $3.1M

  Subcontracted by this company · 2 sub-awards · latest Mar 27, 2025

  • Defense Health Agency
  • “PHYSIOLOGIC AGE OF WHOLE BLOOD”
  • “DETERMINE WHETHER PREHOSPITAL LOW TITER WHOLE BLOOD AS COMPARED TO STANDARD PREHOSPITAL RESUSCITATION RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK. DETERMINE WHETHER PREHOSPITAL OLD WHOLE BLOOD (AGE > 14 DAYS) AS COMPARED TO YOUNG WHOLE BLOOD (AGE ‰¤ 14 DAYS) IS ASSOCIATED WITH EQUIVALENT CLINICAL OUTCOMES, HEMOSTASIS, PREVENTION OF COAGULOPATHY, ANDPLATELET FUNCTION IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK.”
• THE REGENTS OF THE UNIVERSITY OF COLORADO

  UEI MW8JHK6ZYEX8 · not in the directory yet

  $2.1M

  Subcontracted by this company · 2 sub-awards · latest Jan 23, 2026

  • Defense Health Agency
  • Office of Assistant Secretary for Preparedness and Response
  • “TO SERVE AS A CLINICAL SITE FOR LITES STUDY TASK ORDER 010: CALCIUM AND VASOPRESSIN FOLLOWING INJURY EARLY RESUSCITATION (CAVALIER) TRIAL, A MULTI-YEAR, PHASE II DOUBLE-BLINDED, MULTI-CENTER, PREHOSPITAL AND EARLY IN-HOSPITAL RANDOMIZED TRIAL DESIGNED TO DETERMINE WHETHER PREHOSPITAL CALCIUM, EARLY IN-HOSPITAL VASOPRESSIN, OR BOTH AS COMPARED TO PLACEBO RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK.”
  • “THE OVERALL OBJECTIVE OF THIS PROJECT IS TO PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFETHREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CHILDREN. THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES CLINICAL ACTIVITIES (THE CONDUCT OF A MULTICENTER RANDOMIZED CLINICAL TRIAL IN CHILDREN) AS WELL AS RELATED REGULATORY ACTIVITIES (OBTAINING IND FROM FDA FOR USE OF EXCEPTION TO INFORMED CONSENT (EFIC) THAT IS REQUIRED FOR THE CLINICAL TRIAL, AND SINGLE IRB APPROVAL TO ENSURE ETHICAL AND APPROPRIATE CONDUCT OF THE CLINICAL TRIAL).”
• UNIVERSITY OF WASHINGTON

  UEI HD1WMN6945W6 · not in the directory yet

  $1.7M

  Subcontracted by this company · 2 sub-awards · latest May 15, 2026

  • Defense Health Agency
  • “SERVE AS A CLINICAL SITE FOR TASK ORDER 010”
  • “OPEN LABEL, MULTI-CENTER, PREHOSPITAL RANDOMIZED TRIAL TO DETERMINE WHETHER PREHOSPITAL LOW TITER WHOLE BLOOD AS COMPARED TO STANDARD PREHOSPITAL RESUSCITATION RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK.”
• CINCINNATI UNIV OF

  UEI DZ4YCZ3QSPR5 · not in the directory yet

  $1.3M

  Subcontracted by this company · 2 sub-awards · latest Apr 22, 2026

  • Defense Health Agency
  • “OPEN LABEL, MULTI-CENTER, PREHOSPITAL RANDOMIZED TRIAL TO DETERMINE WHETHER PREHOSPITAL LOW TITER WHOLE BLOOD AS COMPARED TO STANDARD PREHOSPITAL RESUSCITATION RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS”
  • “SERVE AS A CLINICAL SITE FOR TASK ORDER 006: PREHOSPITAL ANALGESIA INTERVENTION (PAIN) TRIAL, A 4 YEAR (3-YEAR ENROLLMENT) MULTICENTER, PREHOSPITAL, RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL COMPARING FENTANYL VERSUS SUB-DISSOCIATIVE KETAMINE FOR MORTALITY OUTCOME DIFFERENCES, SAFETY AND ANALGESIA IN TRAUMA PATIENTS WITH COMPENSATED SHOCK.”
• ALLEGHENY SINGER RESEARCH INSTITUTE

  UEI F7V2DLFLWJN9 · not in the directory yet

  $1.2M

  Subcontracted by this company · 3 sub-awards · latest Jun 3, 2025

  • Defense Health Agency
  • “PREHOSPITAL AIRWAY CONTROL TRIAL BASE AWARD”
  • “DETERMINE WHETHER PREHOSPITAL CALCIUM, EARLY IN-HOSPITAL VASOPRESSIN, OR BOTH AS COMPARED TO PLACEBO RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK. DETERMINE WHETHER PREHOSPITAL CALCIUM, EARLY IN-HOSPITAL VASOPRESSIN, OR BOTH AS COMPARED TO PLACEBO ARE ASSOCIATED WITH MORTALITY OUTCOMES (6-HOUR, 24-HOUR, IN-HOSPITAL, DEATH FROM HEMORRHAGE AND BRAIN INJURY), BLOOD AND BLOOD COMPONENT TRANSFUSION REQUIREMENTS (6-HOUR AND 24-HOUR), INCIDENCE OF MULTIPLE ORGAN FAILURE (MOF), INCIDENCE OF NOSOCOMIAL INFECTION, TIME TO HEMOSTASIS, INCIDENCE OF COAGULOPATHY BY THROMBOELASTOGRAPHY (TEG), AND ICU-FREE AND HOSPITAL-FREE DAYS.”
  • “THE PAIN TRIAL IS A 4 YEAR (3-YEAR ENROLLMENT) MULTICENTER, PREHOSPITAL, RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL COMPARING FENTANYL VERSUS SUB-DISSOCIATIVE KETAMINE FOR MORTALITY OUTCOME DIFFERENCES, SAFETY, AND ANALGESIA IN TRAUMA PATIENTS WITH COMPENSATED SHOCK.”
• THE ADMINISTRATORS OF TULANE EDUCATIONAL FUND

  UEI XNY5ULPU8EN6

  $1.2M

  Subcontracted by this company · 2 sub-awards · latest Mar 21, 2025

  • Defense Health Agency
  • “PREHOSPITAL AIRWAY CONTROL TRIAL BASE AWARD”
  • “THE AIMS OF THE CALCIUM AND VASOPRESSIN POST-INJURY EARLY RESUSCITATION (CAVALIER) TRIAL ARE TO DETERMINE THE SAFETY AND EFFICACY OF PREHOSPITAL CALCIUM SUPPLEMENTATION AND EARLY IN-HOSPITAL VASOPRESSIN INFUSION AS COMPARED TO STANDARD CARE RESUSCITATION IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK AND TO APPROPRIATELY CHARACTERIZE ANY ADDITIVE EFFECT OF BOTH RESUSCITATION ADJUNCT INTERVENTIONS. CAVALIER'S PRIMARY STUDY OBJECTIVE IS TO DETERMINE WHETHER PREHOSPITAL CALCIUM, EARLY IN-HOSPITAL VASOPRESSIN, OR BOTH AS COMPARED TO PLACEBO RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK. SECONDARY STUDY OBJECTIVES INCLUDE DETERMINING WHETHER THE INTERVENTIONS ARE ASSOCIATED WITH MORTALITY OUTCOMES (6-HOUR, 24-HOUR, IN-HOSPITAL, DEATH FROM HEMORRHAGE AND BRAIN INJURY), BLOOD AND BLOOD COMPONENT TRANSFUSION REQUIREMENTS (6- HOUR AND 24-HOUR), INCIDENCE OF MULTIPLE ORGAN FAILURE (MOF), INCIDENCE OF NOSOCOMIAL INFECTION, TIME TO HEMOSTASIS, INCIDENCE OF COAGULOPATHY BY THROMBOELASTOGRAPHY (TEG), AND ICU-FREE AND HOSPITAL-FREE DAYS.”
• THE MEDICAL COLLEGE OF WISCONSIN, INC.

  UEI E8VWJXMMUQ67

  $1.2M

  Subcontracted by this company · 2 sub-awards · latest Sep 29, 2026

  • Defense Health Agency
  • Office of Assistant Secretary for Preparedness and Response
  • “THIS SUBAWARD IS TO SUPPORT THE MATIC-2 CLINICAL TRIAL, WHICH EXAMINES THE EFFECTIVENESS, SAFETY AND MECHANISMS BETWEEN MULTIPLE RESUSCITATION PRACTICES IN CHILDREN WITH LIFE THREATENING BLEEDING FROM TRAUMATIC INJURY”
  • “SERVE AS A CLINICAL SITE FOR TASK ORDER 006: PREHOSPITAL ANALGESIA INTERVENTION (PAIN) TRIAL, A 4 YEAR (3-YEAR ENROLLMENT) MULTICENTER, PREHOSPITAL, RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL COMPARING FENTANYL VERSUS SUB-DISSOCIATIVE KETAMINE FOR MORTALITY OUTCOME DIFFERENCES, SAFETY AND ANALGESIA IN TRAUMA PATIENTS WITH COMPENSATED SHOCK.”
• REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE

  UEI KMH5K9V7S518 · not in the directory yet

  $1.1M

  Subcontracted by this company · 2 sub-awards · latest Oct 1, 2024

  • Defense Health Agency
  • “THE PAIN TRIAL IS A 4 YEAR (3-YEAR ENROLLMENT) MULTICENTER, PREHOSPITAL, RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL COMPARING FENTANYL VERSUS SUB-DISSOCIATIVE KETAMINE FOR MORTALITY OUTCOME DIFFERENCES, SAFETY, AND ANALGESIA IN TRAUMA PATIENTS WITH COMPENSATED SHOCK.”
  • “LITES TASK ORDER 004 CRISP IS A 4 YEAR (2-YEAR ENROLLMENT) OPEN LABEL, MULTI-CENTER, RANDOMIZED TRIAL DESIGNED TO DETERMINE THE FEASIBILITY, EFFICACY, AND SAFETY OF URGENT RELEASE COLD STORED PLATELETS IN PATIENTS WITH HEMORRHAGIC SHOCK.”
• UNIVERSITY OF MISSISSIPPI MEDICAL CENTER

  UEI X59NJBFL8BJ3 · not in the directory yet

  $1.1M

  Subcontracted by this company · 2 sub-awards · latest May 28, 2024

  • Defense Health Agency
  • “THE AIMS OF THE CALCIUM AND VASOPRESSIN POST-INJURY EARLY RESUSCITATION (CAVALIER) TRIAL ARE TO DETERMINE THE SAFETY AND EFFICACY OF PREHOSPITAL CALCIUM SUPPLEMENTATION AND EARLY IN-HOSPITAL VASOPRESSIN INFUSION AS COMPARED TO STANDARD CARE RESUSCITATION IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK AND TO APPROPRIATELY CHARACTERIZE ANY ADDITIVE EFFECT OF BOTH RESUSCITATION ADJUNCT INTERVENTIONS. CAVALIER'S PRIMARY STUDY OBJECTIVE IS TO DETERMINE WHETHER PREHOSPITAL CALCIUM, EARLY IN-HOSPITAL VASOPRESSIN, OR BOTH AS COMPARED TO PLACEBO RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK. SECONDARY STUDY OBJECTIVES INCLUDE DETERMINING WHETHER THE INTERVENTIONS ARE ASSOCIATED WITH MORTALITY OUTCOMES (6-HOUR, 24-HOUR, IN-HOSPITAL, DEATH FROM HEMORRHAGE AND BRAIN INJURY), BLOOD AND BLOOD COMPONENT TRANSFUSION REQUIREMENTS (6- HOUR AND 24-HOUR), INCIDENCE OF MULTIPLE ORGAN FAILURE (MOF), INCIDENCE OF NOSOCOMIAL INFECTION, TIME TO HEMOSTASIS, INCIDENCE OF COAGULOPATHY BY THROMBOELASTOGRAPHY (TEG), AND ICU-FREE AND HOSPITAL-FREE DAYS.”
  • “LITES TASK ORDER 004 CRISP IS A 4 YEAR (2-YEAR ENROLLMENT) OPEN LABEL, MULTI-CENTER, RANDOMIZED TRIAL DESIGNED TO DETERMINE THE FEASIBILITY, EFFICACY, AND SAFETY OF URGENT RELEASE COLD STORED PLATELETS IN PATIENTS WITH HEMORRHAGIC SHOCK.”
• UNIVERSITY OF TENNESSEE

  UEI X1M1PN3KG3E7

  $805K

  Subcontracted by this company · 1 sub-award · latest Apr 15, 2026

  • Defense Health Agency
  • “OPEN LABEL, MULTI-CENTER, PREHOSPITAL RANDOMIZED TRIAL TO DETERMINE WHETHER PREHOSPITAL LOW TITER WHOLE BLOOD AS COMPARED TO STANDARD PREHOSPITAL RESUSCITATION RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK.”
• DENVER HEALTH AND HOSPITAL AUTHORITY

  UEI MMT4LGM4H9Z5 · not in the directory yet

  $730K

  Subcontracted by this company · 1 sub-award · latest Oct 6, 2025

  • Defense Health Agency
  • “NEW LITES ORDER TASK ORDER 0010 CAVALIER TRIAL”
• UNIVERSITY OF ROCHESTER

  UEI F27KDXZMF9Y8

  $718.3K

  Subcontracted by this company · 1 sub-award · latest Sep 14, 2026

  • Office of Assistant Secretary for Preparedness and Response
  • “THIS SUBAWARD IS TO SUPPORT THE MATIC-2 CLINICAL TRIAL, WHICH EXAMINES THE EFFECTIVENESS, SAFETY AND MECHANISMS BETWEEN MULTIPLE RESUSCITATION PRACTICES IN CHILDREN WITH LIFE THREATENING BLEEDING FROM TRAUMATIC INJURY.”
• UNIVERSITY OF ARIZONA

  UEI ED44Y3W6P7B9 · not in the directory yet

  $711.6K

  Subcontracted by this company · 2 sub-awards · latest Oct 1, 2026

  • Defense Health Agency
  • Office of Assistant Secretary for Preparedness and Response
  • “THIS SUBAWARD IS TO SUPPORT THE MATIC-2 CLINICAL TRIAL, WHICH EXAMINES THE EFFECTIVENESS, SAFETY AND MECHANISMS BETWEEN MULTIPLE RESUSCITATION PRACTICES IN CHILDREN WITH LIFE THREATENING BLEEDING FROM TRAUMATIC INJURY.”
  • “THE AIMS OF THE CALCIUM AND VASOPRESSIN POST-INJURY EARLY RESUSCITATION (CAVALIER) TRIAL ARE TO DETERMINE THE SAFETY AND EFFICACY OF PREHOSPITAL CALCIUM SUPPLEMENTATION AND EARLY IN-HOSPITAL VASOPRESSIN INFUSION AS COMPARED TO STANDARD CARE RESUSCITATION IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK AND TO APPROPRIATELY CHARACTERIZE ANY ADDITIVE EFFECT OF BOTH RESUSCITATION ADJUNCT INTERVENTIONS. CAVALIER'S PRIMARY STUDY OBJECTIVE IS TO DETERMINE WHETHER PREHOSPITAL CALCIUM, EARLY IN-HOSPITAL VASOPRESSIN, OR BOTH AS COMPARED TO PLACEBO RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK. SECONDARY STUDY OBJECTIVES INCLUDE DETERMINING WHETHER THE INTERVENTIONS ARE ASSOCIATED WITH MORTALITY OUTCOMES (6-HOUR, 24-HOUR, IN-HOSPITAL, DEATH FROM HEMORRHAGE AND BRAIN INJURY), BLOOD AND BLOOD COMPONENT TRANSFUSION REQUIREMENTS (6- HOUR AND 24-HOUR), INCIDENCE OF MULTIPLE ORGAN FAILURE (MOF), INCIDENCE OF NOSOCOMIAL INFECTION, TIME TO HEMOSTASIS, INCIDENCE OF COAGULOPATHY BY THROMBOELASTOGRAPHY (TEG), AND ICU-FREE AND HOSPITAL-FREE DAYS.”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.